Bio-Path Holdings Inc (BPTH):企業の財務・戦略的SWOT分析

◆英語タイトル:Bio-Path Holdings Inc (BPTH) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH17139FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Bio-Path Holdings Inc (Bio-Path) is a clinical stage biotechnology company that develops targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company provides products pipeline such as prexigebersen (Liposomal Grb2 Antisense) and BP1002 (Liposomal Bcl2). Its prexigebersen (Liposomal Grb2 Antisense), is developed for the treatment of Acute Myeloid Leukemia (AML) and solid tumors. Bio-Path’s BP1002 (Liposomal Bcl2) is used for the treatment of lymphoma, leukemia, colon, prostate and breast cancers. The company’s proprietary liposomal delivery and antisense technology platform DNAbilize, is used to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path is headquartered in Bellaire, Texas, the US.

Bio-Path Holdings Inc Key Recent Developments

Apr 05,2021: Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia
Mar 11,2021: Bio-Path Holdings to Present at the 2021 American Association for Cancer Research Annual Meeting
Mar 10,2021: Bio-Path Holdings Reports Full Year 2020 Financial Results
Mar 03,2021: Bio-Path Holdings to Announce Full Year 2020 Financial Results on March 10, 2021
Feb 18,2021: Bio-Path Holdings, Inc. Announces Closing of $13.0 Million Public Offering of Common Stock

This comprehensive SWOT profile of Bio-Path Holdings Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Bio-Path Holdings Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Bio-Path Holdings Inc – Key Information
Bio-Path Holdings Inc – Overview
Bio-Path Holdings Inc – Key Employees
Bio-Path Holdings Inc – Key Employee Biographies
Bio-Path Holdings Inc – Key Operational Heads
Bio-Path Holdings Inc – Major Products and Services
Bio-Path Holdings Inc – History
Bio-Path Holdings Inc – Company Statement
Bio-Path Holdings Inc – Locations And Subsidiaries
Bio-Path Holdings Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Bio-Path Holdings Inc – Business Description
Bio-Path Holdings Inc – Corporate Strategy
Bio-Path Holdings Inc – SWOT Analysis
SWOT Analysis – Overview
Bio-Path Holdings Inc – Strengths
Bio-Path Holdings Inc – Weaknesses
Bio-Path Holdings Inc – Opportunities
Bio-Path Holdings Inc – Threats
Bio-Path Holdings Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Bio-Path Holdings Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Bio-Path Holdings Inc, Key Information
Bio-Path Holdings Inc, Key Ratios
Bio-Path Holdings Inc, Share Data
Bio-Path Holdings Inc, Major Products and Services
Bio-Path Holdings Inc, History
Bio-Path Holdings Inc, Key Employees
Bio-Path Holdings Inc, Key Employee Biographies
Bio-Path Holdings Inc, Key Operational Heads
Bio-Path Holdings Inc, Other Locations
Bio-Path Holdings Inc, Subsidiaries
Bio-Path Holdings Inc, Key Competitors
Bio-Path Holdings Inc, SWOT Analysis
Bio-Path Holdings Inc, Ratios based on current share price
Bio-Path Holdings Inc, Annual Ratios
Bio-Path Holdings Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Bio-Path Holdings Inc (BPTH):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Stallergenes Greer plc (STAGR):企業の財務・戦略的SWOT分析
    Stallergenes Greer plc (STAGR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • GlaxoSmithKline Plc (GSK)-医療機器分野:企業M&A・提携分析
    Summary GlaxoSmithKline Plc (GSK) is a healthcare company, which focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of respiratory, cancer, cardiovascular, HIV and infectious diseases, respira …
  • QEP Resources Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    QEP Resources Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary QEP Resources Inc (QEP) is an independent oil and natural gas exploration and production company. It has operating interests in Northern Region chiefly in North Dakota, Wyoming and Utah; and Southe …
  • Biosensors International Group Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Biosensors International Group Ltd (Biosensors) is a medical devices company. It develops, manufactures and markets medical devices. The company products find application in Interventional cardiology and critical care procedures. The company classifies its products into four categories: Inte …
  • BioMarin Pharmaceutical Inc.:企業の戦略・SWOT・財務情報
    BioMarin Pharmaceutical Inc. - Strategy, SWOT and Corporate Finance Report Summary BioMarin Pharmaceutical Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Entergy Corporation (ETR):電力:M&Aディール及び事業提携情報
    Summary Entergy Corporation (Entergy) is an integrated energy company that generates, transmits, distributes and sells electricity. The company generates electricity from various sources including natural gas, nuclear, coal, hydroelectric, solar and oil based power plants. Entergy also operates natu …
  • Electricity Supply Board-エネルギー分野:企業M&A・提携分析
    Summary Electricity Supply Board (ESB) owned by Irish Government, is a diversified and vertically integrated utility that generates, transmits, and distributes and supplies electricity and gas. The company builds, owns and maintains transmission and distribution networks. It offers meter reading, an …
  • First Light Biosciences Inc:企業の製品パイプライン分析2018
    Summary First Light Biosciences Inc (FLB) is a medical device company that develops and manufactures automated medical diagnostic products for the detection of healthcare associated infections. The company’s product includes multipath analyzer system. Its multipath analyzer system detects resistant …
  • Sumitomo Bakelite Co Ltd (4203):企業の戦略的SWOT分析
    Sumitomo Bakelite Co Ltd (4203) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Excelsior Gold Limited (EXG):企業の財務・戦略的SWOT分析
    Excelsior Gold Limited (EXG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Cellectis SA (ALCLS):企業の財務・戦略的SWOT分析
    Summary Cellectis SA (Cellectis) is a clinical-stage biopharmaceutical company that research, develop and commercialise rational genome engineering technologies. The company pioneers gene editing company, deploying core proprietary technologies to develop off-the-shelf immunotherapies to target and …
  • Siemens Aktiengesellschaft:戦略・SWOT・企業財務分析
    Siemens Aktiengesellschaft - Strategy, SWOT and Corporate Finance Report Summary Siemens Aktiengesellschaft - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • New Carolin Gold Corp:企業の戦略・SWOT・財務情報
    New Carolin Gold Corp - Strategy, SWOT and Corporate Finance Report Summary New Carolin Gold Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Salling Group AS:企業の戦略的SWOT分析
    Salling Group AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • GrafTech International Ltd:企業の戦略・SWOT・財務分析
    GrafTech International Ltd - Strategy, SWOT and Corporate Finance Report Summary GrafTech International Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • STMicroelectronics NV (STM):医療機器:M&Aディール及び事業提携情報
    Summary STMicroelectronics NV (STM) is a semiconductor company. It develops, manufactures, and markets a wide range of products, including discrete and standard commodity components, full custom devices and semi-custom devices and application-specific standard products, and application-specific inte …
  • Dentsply Sirona, Inc.:企業の戦略・SWOT・財務情報
    Dentsply Sirona, Inc. - Strategy, SWOT and Corporate Finance Report Summary Dentsply Sirona, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Rheonix Inc:企業の製品パイプライン分析2018
    Summary Rheonix Inc (Rheonix) is a medical equipment company that develops molecular diagnostic products. The company offers automated and integrated molecular testing device. It develops Rheonix CARD cartridge technology which penetrates molecular testing markets from diagnostics labs to applied ma …
  • Brigham and Women’s Hospital-医療機器分野:企業M&A・提携分析
    Summary Brigham and Women's Hospital (BWH) is a healthcare service provider that offers patient care services. The hospital offers care coordination, ethics consultation, interpreter services, Kessler library, nutrition, patient and family relations, pharmacy, security and safety, and spiritual care …
  • Teijin Ltd (3401):製薬・医療:M&Aディール及び事業提携情報
    Summary Teijin Ltd (Teijin) is a technology driven holding company offering solutions in the areas of information and electronics, healthcare, environment and energy and safety and protection. It focuses on the manufacture and sale of aramid fiber, carbon fiber products, synthetic fiber, films, poly …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆